SCHEDULE 13G/A: Sphera Funds Management Reduces Stake in Chemomab Therapeutics Below 5%
Beneficial Ownership Disclosure
Sphera Funds Management and its affiliates have reported a beneficial ownership of 4.78% in Chemomab Therapeutics Ltd.'s American Depository Shares, marking a reduction below the 5% threshold.
Summary
- Sphera Funds Management Ltd., Sphera Global Healthcare GP Ltd., and Sphera Global Healthcare Management LP collectively reported beneficial ownership of 900,428 American Depository Shares (ADSs) of Chemomab Therapeutics Ltd. as of March 31, 2025.
- This ownership represents 4.78% of the total outstanding ADSs of Chemomab Therapeutics Ltd.
- The percentage is based on 18,856,611 ADSs outstanding as of December 31, 2024, as reported in Chemomab's Annual Report on Form 20-F filed on April 4, 2025.
- Each ADS represents 20 ordinary shares, with 377,132,220 ordinary shares outstanding as of December 31, 2024.
- This filing is an Amendment No. 1 to a Schedule 13G, indicating a change in beneficial ownership that now falls below the 5% reporting threshold.
Sentiment
Score: 4
Explanation: The sentiment is slightly negative as the filing indicates a reduction in a significant institutional stake, which can be interpreted as a lack of conviction or a strategic divestment by the investor.
Negatives
- The reduction in beneficial ownership below the 5% threshold by Sphera Funds Management and its affiliates could be interpreted by some investors as a decrease in conviction or a strategic divestment.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of beneficial ownership and does not provide specific industry context or trends beyond the fact that a healthcare-focused fund is investing in a therapeutics company.
Stakeholder Impact
- Shareholders: May interpret the reduction in institutional ownership as a negative signal, potentially impacting share price perception.
Key Dates
| Date | Description |
|---|---|
| 2024-08-20 | Date of previous Schedule 13G filing (referenced for Joint Filing Agreement). |
| 2024-12-31 | Date as of which 18,856,611 ADSs and 377,132,220 ordinary shares of Chemomab Therapeutics were outstanding, as reported in the Issuer's Form 20-F. |
| 2025-03-31 | Date of event which requires the filing of this Schedule 13G Amendment (change in beneficial ownership). |
| 2025-04-04 | Date Chemomab Therapeutics Ltd. filed its Annual Report on Form 20-F with the SEC. |
| 2025-04-10 | Signature date of the Schedule 13G Amendment. |
Keywords
Chemomab Therapeutics, Sphera Funds Management, SEC filing, Schedule 13G, beneficial ownership, ADSs, investment, shareholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.